Form 4: 10X Fund Reduces Galectin Therapeutics Stake

10X Fund, L.P., a 10% owner and director of Galectin Therapeutics Inc., reported an in-kind distribution and a sale of common stock.

Summary

• 10X Fund, L.P., a 10% owner and director of Galectin Therapeutics Inc. (GALT), reported transactions involving the company's common stock.
• On November 24, 2025, 10X Fund, L.P. distributed 24,000 shares of common stock in an in-kind distribution to a withdrawing limited partner, which was exempt from Section 16(b).
• On December 16, 2025, 10X Fund, L.P. sold 30,681 shares of common stock at a weighted average price of $6.66 per share.
• Following these reported transactions, 10X Fund, L.P. directly beneficially owns 5,614,457 shares of Galectin Therapeutics Inc. common stock.
• 10X Capital Management, LLC, as the general partner of 10X Fund, L.P., and James C. Czirr, as the manager of 10X Capital Management, LLC, may be deemed to have indirect beneficial ownership but disclaim ownership except to the extent of their pecuniary interest.

Sentiment

Score: 3

Explanation: The filing reports a significant insider sale by a 10% owner and director, which can be interpreted as a negative signal regarding management's confidence or valuation.

Negatives

• A 10% owner and director, 10X Fund, L.P., reduced its stake in Galectin Therapeutics Inc. by selling 30,681 shares at an average price of $6.66 per share.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The sale by a significant insider and director may lead to negative sentiment and potentially influence the stock price downwards, signaling a lack of confidence or belief in full valuation by a key stakeholder.

Key Dates

Recommendation

The sale of shares by a 10% owner and director, 10X Fund, L.P., suggests a reduction in conviction or a belief that the stock is fully valued, which typically signals a bearish outlook for the stock.

Keywords

GALT, Galectin Therapeutics, 10X Fund, Insider Trading, Form 4, Stock Sale, Beneficial Ownership